

Guochuan Tsai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11817197/guochuan-tsai-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

5,506
citations

27
h-index

36
g-index

36
ext. papers

5,869
ext. citations

5.2
avg. IF

5.32
L-index

#	Paper	IF	Citations
34	Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5180-5	3.3	40
33	NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5169-79	3.3	44
32	Assessing and treating cognitive impairment in schizophrenia: current and future. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5127-38	3.3	15
31	NMDA pathology and treatment of schizophrenia. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5118-26	3.3	14
30	Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. <i>Current Pharmaceutical Design</i> , 2010 , 16, 522-37	3.3	210
29	Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission. <i>Recent Patents on CNS Drug Discovery</i> , 2009 , 4, 220-38		11
28	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. <i>Synapse</i> , 2009 , 63, 625-35	2.4	22
27	The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. <i>European Journal of Neuroscience</i> , 2009 , 30, 2308-17	3.5	17
26	Promoter analysis of human glutamate carboxypeptidase II. <i>Brain Research</i> , 2007 , 1170, 1-12	3.7	3
25	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 2006 , 60, 645-9	7.9	148
24	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. <i>Journal of Physiology</i> , 2005 , 563, 777-93	3.9	38
23	A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. <i>Psychopharmacology</i> , 2005 , 179, 144-50	4.7	88
22	Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 8485-90	11.5	173
21	NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. <i>International Review of Neurobiology</i> , 2004 , 59, 491-515	4.4	104
20	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. <i>Psychopharmacology</i> , 2004 , 174, 32-8	4.7	172
19	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 2004 , 55, 452-6	7.9	282
18	Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1003, 318-27	6.5	356

17	Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. <i>Biological Psychiatry</i> , 2002 , 51, 493-7	7.9	85
16	Glutamatergic mechanisms in schizophrenia. <i>Annual Review of Pharmacology and Toxicology</i> , 2002 , 42, 165-79	17.9	515
15	Ionotropic glutamate receptors as therapeutic targets in schizophrenia. <i>CNS and Neurological Disorders</i> , 2002 , 1, 183-9		91
14	A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. <i>Archives of General Psychiatry</i> , 1999 , 56, 21-7		349
13	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. <i>Biological Psychiatry</i> , 1998 , 44, 667-74	7.9	62
12	D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 1998 , 44, 1081-9	7.9	539
11	The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. <i>Annual Review of Medicine</i> , 1998 , 49, 173-84	17.4	325
10	Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. <i>American Journal of Psychiatry</i> , 1998 , 155, 1207-13	11.9	201
9	Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. <i>Archives of General Psychiatry</i> , 1995 , 52, 829-36		375
8	N-acetylaspartate in neuropsychiatric disorders. <i>Progress in Neurobiology</i> , 1995 , 46, 531-40	10.9	352
7	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. <i>Brain Research</i> , 1993 , 629, 305-9	3.7	13
6	Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. <i>Journal of Chemical Neuroanatomy</i> , 1993 , 6, 277-92	3.2	28
5	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). <i>Journal of Comparative Neurology</i> , 1992 , 315, 217-29	3.4	88
4	Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. <i>Brain Research</i> , 1991 , 556, 151-6	3.7	96
3	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1990 , 28, 18-25	9.4	541
2	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. <i>Neuroscience Letters</i> , 1989 , 100, 295-300	3.3	45
1	Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. <i>Journal of Neurochemistry</i> , 1988 , 51, 1956-9	6	64